The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
|Articles|June 1, 1997
The American Journal of Managed Care
- June 1997
- Volume 3
- Issue 6
Prostate Cancer Screening
Advertisement
Articles in this issue
over 29 years ago
Asthma Treatment Costs Using Inhaled Corticosteroidsover 29 years ago
Costs, True Costs, and Whose Costs in Economic Analyses in Medicine?over 29 years ago
Breast Reconstruction After Mastectomyover 29 years ago
Breast-Feeding and Managed CareAdvertisement
Related to this article
Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.
Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5